Seaport presents at J.P. Morgan Healthcare Conference 2024

43rd Annual J.P. Morgan Healthcare Conference

Seaport presents at Stifel Healthcare Conference 2024

Stifel Healthcare Conference

VIEW

Nature Metabolism

Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity

VIEW

Frontiers in Pharmacology

Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport

VIEW

Journal of Controlled Release

Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice

VIEW

American College of Neuropsychopharmacology (ACNP) 2024

SPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers

VIEW

Society of Biological Psychiatry (SOBP) 2024

A First-in-Human Phase 1 Study of SPT-300, a First-in-Class Orally Bioavailable Prodrug of the NeurosteroidAllopregnanolone That is Absorbed via the Lymphatic System

VIEW

Society of Biological Psychiatry (SOBP) 2024

SPT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Phase 2a Study in Healthy Participants

VIEW

101 Seaport Blvd
Seaport Boston, MA 02210

General info: info@seaporttx.com
Media: publicrelations@seaporttx.com

www.SeaportTx.com
@SeaportTx
LinkedIn

Seaport Therapeutics
101 Seaport Blvd
Seaport Boston, MA 02210

info@seaporttx.com
Privacy Policy
Terms of Use

© 2024 Seaport Therapeutics